Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced <i>RET</i> fusion-positive non-small-cell lung cancer and thyroid cancer, and <i>RET</i>-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial.
Journal Information
Full Title: Ther Adv Med Oncol
Abbreviation: Ther Adv Med Oncol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"SL, XZ, YS, DH, LW, QJ, CZ, JZ, YG, MhG, MG, and YC claim no conflict of interest. DD, JS, and WZ are employees of Eli Lilly and Company."
Funding Disclosure
Evidence found in paper:
"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Eli Lilly and Company (Pharmaceutical Company)."
Protocol Registration
Evidence found in paper:
"Trail registration:: This study was registered at ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT04280081) ClinicalTrials.gov Identifier: NCT04280081."
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025